A study comparing cardiovascular effects of ticagrelor and clopidogrel in patients with Peripheral Artery Disease - EUCLID

Study identifier:D5135C00001

ClinicalTrials.gov identifier:NCT01732822

EudraCT identifier:2011-004616-36

CTIS identifier:N/A

Study Complete

Official Title

A randomized, double-blind, parallel group, multicentre phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischemic stroke in patients with established Peripheral Artery Disease (EUCLID Examining Use of tiCagreLor In paD)

Medical condition

Peripheral Artery Disease

Phase

Phase 3

Healthy volunteers

No

Study drug

Ticagrelor, Clopidogrel

Sex

All

Actual Enrollment

13885

Study type

Interventional

Age

50 Years - 130 Years

Date

Study Start Date: 04 Dec 2012
Primary Completion Date: 26 Sept 2016
Study Completion Date: 26 Sept 2016

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Prevention

Verification:

Verified 01 Sept 2017 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria